These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 37575237)
1. NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma. Miftah H; Naji O; Ssi SA; Ghouzlani A; Lakhdar A; Badou A Front Immunol; 2023; 14():1139268. PubMed ID: 37575237 [TBL] [Abstract][Full Text] [Related]
2. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma. Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C Front Immunol; 2022; 13():1052692. PubMed ID: 36685506 [TBL] [Abstract][Full Text] [Related]
3. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124 [TBL] [Abstract][Full Text] [Related]
4. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy. Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K Front Immunol; 2023; 14():1166377. PubMed ID: 37063864 [TBL] [Abstract][Full Text] [Related]
5. MELK is a prognostic biomarker and correlated with immune infiltration in glioma. Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X Front Neurol; 2022; 13():977180. PubMed ID: 36353126 [TBL] [Abstract][Full Text] [Related]
6. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Klepsch V; Hermann-Kleiter N; Baier G Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma. Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z Cells; 2022 Dec; 11(24):. PubMed ID: 36552760 [TBL] [Abstract][Full Text] [Related]
8. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas. Tian QS; Zhang Q; Huang W Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806 [TBL] [Abstract][Full Text] [Related]
9. Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6. Klepsch V; Siegmund K; Baier G Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073258 [TBL] [Abstract][Full Text] [Related]
10. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma. Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612 [TBL] [Abstract][Full Text] [Related]
11. Diverse Macrophages Constituted the Glioma Microenvironment and Influenced by PTEN Status. Zhou F; Shi Q; Fan X; Yu R; Wu Z; Wang B; Tian W; Yu T; Pan M; You Y; Wang Y Front Immunol; 2022; 13():841404. PubMed ID: 35265085 [TBL] [Abstract][Full Text] [Related]
12. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489 [TBL] [Abstract][Full Text] [Related]
13. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas. Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B Front Immunol; 2023; 14():1065062. PubMed ID: 37325664 [TBL] [Abstract][Full Text] [Related]
14. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas. Li J; Zhang Y; Qu Z; Ding R; Yin X Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373 [TBL] [Abstract][Full Text] [Related]
15. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis. Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W Front Immunol; 2021; 12():557994. PubMed ID: 34220791 [TBL] [Abstract][Full Text] [Related]
16. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment. Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z Front Immunol; 2021; 12():691811. PubMed ID: 34489938 [TBL] [Abstract][Full Text] [Related]
17. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas. He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672 [TBL] [Abstract][Full Text] [Related]
18. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma. Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A Front Immunol; 2022; 13():961933. PubMed ID: 35990696 [TBL] [Abstract][Full Text] [Related]
19. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. Liu J; Xu K; Ma L; Wang Y Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410 [TBL] [Abstract][Full Text] [Related]
20. High expression of stromal signatures correlated with macrophage infiltration, angiogenesis and poor prognosis in glioma microenvironment. Tian Y; Ke Y; Ma Y PeerJ; 2020; 8():e9038. PubMed ID: 32509446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]